Platform|API|Archive|Contact

Humanexa SignalsPharmaceutical Intelligence

FDA
EMA
MHRA
PMDA
Health Canada

Phase I
Phase II
Phase III
Readouts
Enrollment Signals

Pipeline Tracking
Company Moves
Asset Intelligence
Landscape Reports

Pricing
Access
Commercial
Launch Tracking

Licensing
Acquisitions
Partnerships
Capital Raises

Strategy Catalysts Pricing

Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Powered by Humanexa

Categories

Regulatory
Clinical
Competitive
Markets
M&A Watch
Strategy
Catalyst Tracker

Company

Pricing
Partner with us
Subscribe
Contact
Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

© 2026 Humanexa Signals. All rights reserved.

Intelligence powered by the Humanexa engine.

Company

Moderna

Pharmaceutical intelligence for Moderna with 8 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 4
Catalysts: 4
Assets: 7

Recent signals(4)

CompetitiveJune 27, 2026

Moderna initiates safety and immunogenicity study for RSV vaccines in infants

Moderna is conducting a study to evaluate the safety and immunogenicity of two mRNA vaccines targeting RSV and hMPV in infants.

ClinicalJune 17, 2026

E7 mRNA/LNP vaccine shows promise in treating early-stage HPV tumors in mice

The study demonstrates that the HPV16 E7 mRNA/LNP vaccine induces strong immune responses and tumor regression in early-stage HPV tumors in mice.

ClinicalJune 17, 2026

mRNA-1083 Shows Durable Immune Response and Safety in Adults ≥50 Years

mRNA-1083 demonstrated durable antibody responses against influenza and SARS-CoV-2 for 6 months with a favorable safety profile.

ClinicalJune 16, 2026

NextCOVE trial shows mRNA-1283 vaccine elicits higher nAb responses than mRNA-1273

The mRNA-1283 vaccine met non-inferiority criteria against mRNA-1273 and elicited higher neutralizing antibody responses.

Upcoming catalysts(1)

Phase III Readout

Moderna — mRNA-4157

Personalized cancer vaccine readout could validate mRNA platform beyond infectious disease.

July 15, 2026 · Phase III

Regulatory activity

No signals indexed for this entity yet.

Clinical activity(3)

ClinicalJune 17, 2026

E7 mRNA/LNP vaccine shows promise in treating early-stage HPV tumors in mice

The study demonstrates that the HPV16 E7 mRNA/LNP vaccine induces strong immune responses and tumor regression in early-stage HPV tumors in mice.

ClinicalJune 17, 2026

mRNA-1083 Shows Durable Immune Response and Safety in Adults ≥50 Years

mRNA-1083 demonstrated durable antibody responses against influenza and SARS-CoV-2 for 6 months with a favorable safety profile.

ClinicalJune 16, 2026

NextCOVE trial shows mRNA-1283 vaccine elicits higher nAb responses than mRNA-1273

The mRNA-1283 vaccine met non-inferiority criteria against mRNA-1273 and elicited higher neutralizing antibody responses.

Competitive activity(1)

CompetitiveJune 27, 2026

Moderna initiates safety and immunogenicity study for RSV vaccines in infants

Moderna is conducting a study to evaluate the safety and immunogenicity of two mRNA vaccines targeting RSV and hMPV in infants.

Assets

Pipeline Update →

Trial Update →

Therapeutic areas

HPV-related cancers →

Infectious Disease →

Infectious Disease · COVID-19 →

Infectious Disease · Vaccine →

Oncology · HPV-related cancers →

Indications

HPV-related cancers →

Infectious Disease →

Melanoma (adjuvant) →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.